Vaccinex Statistics
Total Valuation
Vaccinex has a market cap or net worth of 2.41 million. The enterprise value is 2.99 million.
| Market Cap | 2.41M |
| Enterprise Value | 2.99M |
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaccinex has 2.68 million shares outstanding. The number of shares has increased by 352.70% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.68M |
| Shares Change (YoY) | +352.70% |
| Shares Change (QoQ) | +59.04% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 0.64% |
| Float | 1.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.01 |
| PB Ratio | -0.97 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.16 |
| EV / Sales | 4.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.18 |
Financial Position
The company has a current ratio of 0.50
| Current Ratio | 0.50 |
| Quick Ratio | 0.38 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -9,367.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -376.08% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 753.01% |
| Revenue Per Employee | 24,040 |
| Profits Per Employee | -745,360 |
| Employee Count | 27 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.49% in the last 52 weeks. The beta is 1.35, so Vaccinex's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -86.49% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 2.87 |
| Relative Strength Index (RSI) | 50.38 |
| Average Volume (20 Days) | 2,074 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.96 |
Income Statement
In the last 12 months, Vaccinex had revenue of 601,000 and -18.63 million in losses. Loss per share was -8.88.
| Revenue | 601,000 |
| Gross Profit | -11.94M |
| Operating Income | -18.74M |
| Pretax Income | -18.63M |
| Net Income | -18.63M |
| EBITDA | -18.64M |
| EBIT | -18.74M |
| Loss Per Share | -8.88 |
Balance Sheet
The company has 1.11 million in cash and 25,000 in debt, giving a net cash position of 1.08 million or 0.40 per share.
| Cash & Cash Equivalents | 1.11M |
| Total Debt | 25,000 |
| Net Cash | 1.08M |
| Net Cash Per Share | 0.40 |
| Equity (Book Value) | -2.49M |
| Book Value Per Share | -1.55 |
| Working Capital | -2.55M |
Cash Flow
In the last 12 months, operating cash flow was -16.19 million and capital expenditures -22,000, giving a free cash flow of -16.21 million.
| Operating Cash Flow | -16.19M |
| Capital Expenditures | -22,000 |
| Free Cash Flow | -16.21M |
| FCF Per Share | -6.06 |
Margins
| Gross Margin | n/a |
| Operating Margin | -3,117.30% |
| Pretax Margin | -3,100.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vaccinex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -352.70% |
| Shareholder Yield | -352.70% |
| Earnings Yield | -773.44% |
| FCF Yield | -672.74% |
Stock Splits
The last stock split was on February 20, 2024. It was a reverse split with a ratio of 0.0714286.
| Last Split Date | Feb 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0714286 |
Scores
Vaccinex has an Altman Z-Score of -217.06. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -217.06 |
| Piotroski F-Score | n/a |